A Single-center Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 17 Nov 2017 Planned End Date changed from 29 Nov 2017 to 22 Nov 2017.
- 17 Nov 2017 Planned primary completion date changed from 29 Nov 2017 to 22 Nov 2017.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.